๎
๎ผ
๎
Beam Therapeutics Inc
BEAM25.030USD
+0.340+1.38%
์ข
๊ฐย 11/26, 16:00๏ผET๏ผ์์ธ๋ 15๋ถ ์ง์ฐ๋ฉ๋๋ค
2.54B์๊ฐ์ด์ก
์์คP/E TTM
๎
์์ธํ ๋ด์ฉ์ Beam Therapeutics Inc ํ์ฌ
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.
Beam Therapeutics Inc ์ ๋ณด
๎์ข
๋ชฉ ์ฝ๋ BEAM
ํ์ฌ ์ด๋ฆBeam Therapeutics Inc
์์ฅ์ผFeb 06, 2020
CEOMr. John M. Evans
์ง์ ์483
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃFeb 06
์ฃผ์238 Main Street
๋์CAMBRIDGE
์ฆ๊ถ ๊ฑฐ๋์NASDAQ Global Select Consolidated
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ02142
์ ํ18573278775
์น์ฌ์ดํธhttps://beamtx.com/
์ข
๋ชฉ ์ฝ๋ BEAM
์์ฅ์ผFeb 06, 2020
CEOMr. John M. Evans
Beam Therapeutics Inc์ ํ์ฌ ์์์ง
๎์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Dr. Giuseppe Ciaramella, Ph.D.
Dr. Giuseppe Ciaramella, Ph.D.
President
President
107.78K
-6.45%
Dr. Amy Simon, M.D.
Dr. Amy Simon, M.D.
Chief Medical Officer
Chief Medical Officer
1.74K
-97.47%
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Dr. Christine P. Bellon, Ph.D.
Dr. Christine P. Bellon, Ph.D.
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
Mr. Sravan K. Emany
Mr. Sravan K. Emany
Chief Financial and Principal Financial Officer
Chief Financial and Principal Financial Officer
--
--
Mr. John M. Evans
Mr. John M. Evans
Chief Executive Officer, Principal Accounting Officer, Director
Chief Executive Officer, Principal Accounting Officer, Director
--
--
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Independent Director
Independent Director
--
--
Ms. Christi Shaw
Ms. Christi Shaw
Independent Director
Independent Director
--
--
Dr. Mark C. Fishman, M.D.
Dr. Mark C. Fishman, M.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Graham K. Cooper
Mr. Graham K. Cooper
Independent Director
Independent Director
--
--
๋ ๋ณด๊ธฐ
์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Dr. Giuseppe Ciaramella, Ph.D.
Dr. Giuseppe Ciaramella, Ph.D.
President
President
107.78K
-6.45%
Dr. Amy Simon, M.D.
Dr. Amy Simon, M.D.
Chief Medical Officer
Chief Medical Officer
1.74K
-97.47%
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Dr. Christine P. Bellon, Ph.D.
Dr. Christine P. Bellon, Ph.D.
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
Mr. Sravan K. Emany
Mr. Sravan K. Emany
Chief Financial and Principal Financial Officer
Chief Financial and Principal Financial Officer
--
--
Mr. John M. Evans
Mr. John M. Evans
Chief Executive Officer, Principal Accounting Officer, Director
Chief Executive Officer, Principal Accounting Officer, Director
--
--
์์ต ๋ถ์
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
์ง์ญ๋ณUSD
์ด๋ฆ
์์ต
๋น์จ
United States
8.47M
0.00%
์ฌ์
๋ณ
์ง์ญ๋ณ
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
์ฃผ์ ๋ณด์ ํต๊ณ
๋ง์ง๋ง ์
๋ฐ์ดํธ: Sun, Nov 16
๋ง์ง๋ง ์
๋ฐ์ดํธ: Sun, Nov 16
์ฃผ์ฃผ
์ฃผ์ฃผ ์ ํ
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น์จ
Fidelity Management & Research Company LLC
11.11%
ARK Investment Management LLC
10.88%
Farallon Capital Management, L.L.C.
9.92%
The Vanguard Group, Inc.
9.09%
BlackRock Institutional Trust Company, N.A.
6.68%
๊ธฐํ
52.33%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น์จ
Fidelity Management & Research Company LLC
11.11%
ARK Investment Management LLC
10.88%
Farallon Capital Management, L.L.C.
9.92%
The Vanguard Group, Inc.
9.09%
BlackRock Institutional Trust Company, N.A.
6.68%
๊ธฐํ
52.33%
์ฃผ์ฃผ ์ ํ
์ฃผ์ฃผ
๋น์จ
Investment Advisor
56.24%
Investment Advisor/Hedge Fund
20.11%
Hedge Fund
16.85%
Venture Capital
4.79%
Research Firm
2.41%
Individual Investor
1.27%
Bank and Trust
1.22%
Pension Fund
0.28%
Family Office
0.06%
๊ธฐ๊ด ์ฃผ์ ๋ณด์
๎๋ง์ง๋ง ์
๋ฐ์ดํธ: Wed, Oct 1
๋ง์ง๋ง ์
๋ฐ์ดํธ: Wed, Oct 1
๋ณด๊ณ ๊ธฐ๊ฐ
๊ธฐ๊ด ์
๋ณด์ ์ฃผ์
๋น์จ
๋ณ๋
2025Q3
539
106.16M
104.63%
-429.74K
2025Q2
537
101.17M
100.03%
+11.84M
2025Q1
562
100.13M
99.59%
+12.37M
2024Q4
542
80.18M
95.83%
-6.23M
2024Q3
539
78.60M
95.42%
-7.95M
2024Q2
538
78.23M
95.09%
-5.21M
2024Q1
550
76.09M
93.23%
-4.97M
2023Q4
549
75.48M
92.79%
-3.23M
2023Q3
554
74.84M
95.14%
-3.35M
2023Q2
566
72.06M
94.81%
-2.24M
๋ ๋ณด๊ธฐ
์ฃผ์ฃผ ํ๋
๎์ด๋ฆ
๋ณด์ ์ฃผ์
๋น์จ
๋ณ๋
Chg %
๋ ์ง
Fidelity Management & Research Company LLC
12.53M
12.38%
+4.93M
+64.83%
Jun 30, 2025
ARK Investment Management LLC
10.41M
10.29%
+1.56M
+17.66%
Jul 31, 2025
Farallon Capital Management, L.L.C.
10.01M
9.9%
+85.00K
+0.86%
Jun 30, 2025
The Vanguard Group, Inc.
9.69M
9.58%
+837.64K
+9.47%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
6.72M
6.64%
-37.63K
-0.56%
Jun 30, 2025
Amova Asset Management Co., Ltd.
4.73M
4.68%
+462.57K
+10.84%
Jun 30, 2025
ARCH Venture Partners
4.54M
4.49%
--
--
Jun 30, 2025
State Street Investment Management (US)
3.64M
3.6%
+198.15K
+5.76%
Jun 30, 2025
Bellevue Asset Management AG
2.89M
2.86%
+493.36K
+20.59%
Jun 30, 2025
Kynam Capital Management LP
2.42M
2.39%
-100.52K
-3.99%
Jun 30, 2025
๋ ๋ณด๊ธฐ
๊ด๋ จ ETF
๎๋ง์ง๋ง ์
๋ฐ์ดํธ: Thu, Nov 6
๋ง์ง๋ง ์
๋ฐ์ดํธ: Thu, Nov 6
์ด๋ฆ
๋น์จ
ARK Genomic Revolution ETF
4.11%
ARK Innovation ETF
2.75%
Global X Genomics & Biotechnology ETF
2.43%
WisdomTree BioRevolution Fund
2.24%
Virtus LifeSci Biotech Clinical Trials ETF
1%
Franklin Genomic Advancements ETF
0.91%
SPDR S&P Biotech ETF
0.85%
Harbor Health Care ETF
0.51%
Direxion Daily S&P Biotech Bull 3X Shares
0.45%
Invesco Nasdaq Biotechnology ETF
0.25%
๋ ๋ณด๊ธฐ
ARK Genomic Revolution ETF
๋น์จ4.11%
ARK Innovation ETF
๋น์จ2.75%
Global X Genomics & Biotechnology ETF
๋น์จ2.43%
WisdomTree BioRevolution Fund
๋น์จ2.24%
Virtus LifeSci Biotech Clinical Trials ETF
๋น์จ1%
Franklin Genomic Advancements ETF
๋น์จ0.91%
SPDR S&P Biotech ETF
๋น์จ0.85%
Harbor Health Care ETF
๋น์จ0.51%
Direxion Daily S&P Biotech Bull 3X Shares
๋น์จ0.45%
Invesco Nasdaq Biotechnology ETF
๋น์จ0.25%
์ฃผ์ ๋ฐฐ๋น๊ธ
๎์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.
๋ ์ง
๋ฐฐ๋น๊ธ
๊ธฐ์ค์ผ
์ง๊ธ์ผ
๋ฐฐ๋น๋ฝ์ผ
๋ฐ์ดํฐ ์์
์ฃผ์ ๋ถํ
๎๋ ์ง
์ ํ
๋น์จ
๋ฐ์ดํฐ ์์
๋ ์ง
์ ํ
๋น์จ
๋ฐ์ดํฐ ์์
์์ฃผ ๋ฌป๋ ์ง๋ฌธ
Beam Therapeutics Inc์ ์์ 5๋ ์ฃผ์ฃผ๋ ๋๊ตฌ์ธ๊ฐ์?
๎Beam Therapeutics Inc์ ์์ 5๋ ์ฃผ์ฃผ๋ ๋ค์๊ณผ ๊ฐ์ต๋๋ค:
Fidelity Management & Research Company LLC๋ 12.53M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 12.38%๋ฅผ ์ฐจ์งํฉ๋๋ค.
ARK Investment Management LLC๋ 10.41M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 10.29%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Farallon Capital Management, L.L.C.๋ 10.01M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 9.90%๋ฅผ ์ฐจ์งํฉ๋๋ค.
The Vanguard Group, Inc.๋ 9.69M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 9.58%๋ฅผ ์ฐจ์งํฉ๋๋ค.
BlackRock Institutional Trust Company, N.A.๋ 6.72M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 6.64%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Fidelity Management & Research Company LLC๋ 12.53M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 12.38%๋ฅผ ์ฐจ์งํฉ๋๋ค.
ARK Investment Management LLC๋ 10.41M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 10.29%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Farallon Capital Management, L.L.C.๋ 10.01M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 9.90%๋ฅผ ์ฐจ์งํฉ๋๋ค.
The Vanguard Group, Inc.๋ 9.69M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 9.58%๋ฅผ ์ฐจ์งํฉ๋๋ค.
BlackRock Institutional Trust Company, N.A.๋ 6.72M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 6.64%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Beam Therapeutics Inc์ ์์ 3๋ ์ฃผ์ฃผ ์ ํ์ ๋ฌด์์ธ๊ฐ์?
๎Beam Therapeutics Inc์ ์ฃผ์ ์ฃผ์ฃผ ์ ํ ์์ 3๊ฐ์ง๋
Fidelity Management & Research Company LLC
ARK Investment Management LLC
Farallon Capital Management, L.L.C.์ ๋๋ค.
Fidelity Management & Research Company LLC
ARK Investment Management LLC
Farallon Capital Management, L.L.C.์ ๋๋ค.
Beam Therapeutics Inc(BEAM)์ ์ฃผ์์ ๋ณด์ ํ ๊ธฐ๊ด์ ๋ช ๊ฐ์ ๋๊น?
๎2025Q3 ๊ธฐ์ค์ผ๋ก, Beam Therapeutics Inc์ ์ฃผ์์ ๋ณด์ ํ ๊ธฐ๊ด์ ์ด 539๊ณณ์ด๋ฉฐ, ์ด๋ค์ด ๋ณด์ ํ ์ฃผ์์ ์ด ๊ฐ์น๋ ์ฝ 106.16M๋ก ์ ์ฒด ๋ฐํ ์ฃผ์์ 104.63%๋ฅผ ์ฐจ์งํฉ๋๋ค. ์ด๋ 2025Q2 ๋๋น 4.60% ์ฆ๊ฐํ ์์น์
๋๋ค.
Beam Therapeutics Inc์ ์ต๋ ์์ต์์ ๋ฌด์์ธ๊ฐ์?
๎FY2025Q2 ๊ธฐ์ค, Beam Therapeutics Inc์ -- ๋ถ๋ฌธ์ด ๊ฐ์ฅ ๋์ ๋งค์ถ์ ๊ธฐ๋กํ์ผ๋ฉฐ, ๊ธ์ก์ --๋ก ์ ์ฒด ๋งค์ถ์ --%๋ฅผ ์ฐจ์งํ์ต๋๋ค.
